Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV‐infected patients in a real‐life cohort from Latin America
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Medical Virology"
DOI: 10.1002/jmv.24816
Abstract: Information about the use of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) in real‐clinical practice in Latin America is scarce. We aimed to confirm safety and effectiveness of OBV/PTV/r/DSV ± RBV therapy in real‐world setting. We analyzed a cohort of patients with… read more here.
Keywords: latin america; hcv; obv ptv; ptv dsv ... See more keywords
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease
Sign Up to like & getrecommendations! Published in 2019 at "Kidney International Reports"
DOI: 10.1016/j.ekir.2018.10.005
Abstract: Introduction Patients with hepatitis C virus (HCV) infection and chronic kidney disease (CKD) are a high-priority population for treatment. Methods We performed a post hoc pooled efficacy and safety analysis that included HCV genotype 1–infected… read more here.
Keywords: ritonavir dasabuvir; ombitasvir paritaprevir; obv ptv; disease ... See more keywords
Real World Effectiveness of Treatment With OBV/PTV/R ± DSV In HCV Patients With Cirrhosis In Poland
Sign Up to like & getrecommendations! Published in 2017 at "Value in Health"
DOI: 10.1016/j.jval.2017.08.2262
Abstract: Chronic hepatitis C virus infection is one of the leading causes of slowly progressive hepatic fibrosis, which, if untreated, leads to cirrhosis, hepatic failure, and increased risk of death. In HCV infected patients, compared to… read more here.
Keywords: ptv dsv; treatment; hcv; cirrhosis ... See more keywords